{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'A drug-related anaphylactic reaction.', 'A persistently severe drug-related AE that does not abate to mild or moderate', 'intensity at least 2 weeks prior to the next scheduled dose.', 'Severe drug-related hyperglycemia (e.g., blood glucose > 250 mg/dL) that does', 'not abate to mild or moderate intensity with anti-diabetic treatment (dose may be', 'skipped up to 2 times prior to permanently discontinuing study drug; see', 'Section 9.4.6.3.2 for details).', 'Diagnosed or suspected IBD (e.g., diarrhea with or without blood or rectal', 'bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or', 'incontinence for more than 4 weeks without a confirmed alternative diagnosis OR', 'endoscopic or radiologic evidence of enteritis/colitis without a confirmed', 'alternative diagnosis.', 'Lack of Efficacy. Removal of a subject from the study is at the discretion of the', 'Investigator and may occur if the Investigator determines that study drug administration', 'is not benefitting the subject and eye symptoms linked to progressing disease worsen', 'posing an unacceptable risk to the subject. The specific care of the subject is best', \"determined by the Investigator and managing physician(s) involved in the subject's care\", 'and may require removal from the study. All subjects are free to withdraw from study', 'participation at any time, for any reason, allowing them to receive any specific treatment', 'for TED that is considered necessary per their treating physician and local standard of', 'care.', 'Non-Compliance with Study Drug/Other/Protocol Deviations. The subject has a', 'significant protocol deviation, does not comply with study drug administration schedule,', 'or fails to adhere to other study requirements as stated in the protocol.', 'Lost to Follow-Up. The subject does not return to the clinic for scheduled assessments,', \"and does not respond to the site's attempts to contact the subject.\", 'Withdrawal by Subject/Guardian. The subject wishes to withdraw from the study. The', 'clinical site should attempt to determine the underlying reason for the voluntary', 'withdrawal and document it on the eCRF; if the underlying reason is documented as an', 'AE or lack of efficacy, the category of withdrawal should be marked in the corresponding', 'category and not as voluntary withdrawal.', 'Study Terminated by Sponsor. The Sponsor, IRB/IEC, or regulatory agency terminates', 'the study.', 'Pregnancy.', 'Subjects who prematurely discontinue study drug dosing prior to Week 21 of the Treatment', 'Period will return to the clinic and undergo the scheduled Week 24 assessments and will be', 'encouraged to participate in the Follow-Up Period unless they initiated another intervention due', 'to lack of efficacy. Subjects who enter the Follow-Up Period but prematurely discontinue study', 'participation prior to 48 weeks following the Treatment Period will return for a final visit and', 'undergo the scheduled Week 72 assessments prior to study discharge. Subjects who discontinue', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 69 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'due to an AE should be followed until resolution or stabilization of the AE, or an adequate', 'explanation for the event is obtained.', '9.3.4 Criteria for Responders Who Relapse', 'If subjects meet the response criteria at Week 24 but subsequently experience a disease relapse', 'during the 48-week Follow-Up Period, they will have the option to enter the open-label study', 'with teprotumumab (HZNP-TEP-302) and receive 8 infusions of teprotumumab. The criteria to', 'determine relapse is the following:', 'Increase in proptosis of > 2 mm in the study eye since Week 24, or', 'An increase in CAS > 2 points since Week 24 with an absolute CAS of > 4 in the study', 'eye following the Week 24 Visit.', 'In addition to one of the bullet points above, the Investigator should also consider the', \"subject's symptomology to ensure a relapse has occurred (e.g., new onset of double\", 'vision).', '9.3.5', 'Replacement Policy', '9.3.5.1 Subjects', 'No subject prematurely discontinued from the study for any reason will be replaced.', '9.3.5.2 Centers', 'A center may be closed and/or replaced for the following administrative reasons:', 'Excessively slow recruitment.', 'Poor protocol adherence.', '9.3.5.3 Screen Failures', 'Subjects who do not meet all of the inclusion criteria or meet any of the exclusion criteria will be', 'considered screen failures. Screen failures may be allowed to rescreen for the study if both the', 'Investigator and Sponsor are in agreement regarding rescreening and if the Investigator', 'determines that they can satisfy all of the eligibility criteria. Based on the TED01RV study, the', 'expected screen failure rate is 20 - 25% [Smith et al, 2017].', '9.4', 'Treatments', '9.4.1', 'Treatments Administered', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff. On', 'Day 1 of the double-masked Treatment Period, subjects will be randomized in a 1:1 ratio', '(stratified by tobacco use status) to receive infusions of either:', '1.', 'Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the', 'remaining 7 infusions), or', '2.', 'Placebo (q3W for all 8 infusions).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 70 of 117']\n\n###\n\n", "completion": "END"}